Development of a Quality of Life Decision-Making Model for Older Patients with Acute Myeloid Leukemia
The purpose of this study is to describe the differences in quality of life (QOL) among newly diagnosed patients diagnosed with acute myeloid leukemia (AML) to help design a patient decision-making QOL model for aligning patients' choice of treatment with what matters the most to them.
Specific Aim #1 Describe differences in QOL among newly diagnosed AML patients (> 60 years of age) receiving intensive versus non-intensive chemotherapy (at baseline and 30, 60, 90- and 180-days post treatment). Specific Aim #2 Identify the individual clinical disease characteristics (blast percentage, transfusion dependence, cytogenetic risk group) and patient factors (age, comorbidities, functional status, and physical symptoms) that may predict QOL among newly diagnosed older AML patients treated at the 2 different treatment intensities. Specific Aim #3 Design a patient decision-making model integrating significant clinical disease and patient factor predictors of QOL for newly diagnosed AML patients deciding between intensive and non-intensive treatment. Information will be provided to patients concerning common symptoms, overall QOL, and survival with various treatment
- Inclusion Criteria:
- 60 years of age or older
- Newly diagnosed with pathology-confirmed diagnosis of Acute Myeloid Leukemia
- Within 7 days of starting a new treatment
- Must be able to read and speak English at the 8th grade level
- Exclusion Criteria:
- Under 60 years of age
- Other malignancy, dementia, traumatic brain injury or individuals with central nervous system involvement of their leukemia
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.